

NDA 20-273/SE8-004

Westwood Squibb Pharmaceutical Inc.
Attention: David L. Silberstein
Manager, Regulatory Affairs
100 Forest Avenue
Buffalo, New York 14213-1091

Dear Mr. Silberstein:

Please refer to your supplemental new drug application dated July 8, 1998, received July 8, 1998, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Dovonex (calcipotriene ointment) Ointment, 0.005%.

We also acknowledge receipt of your submission dated January 8 and 14, 1999.

This supplemental new drug application provides for the use of Dovonex (calcipotriene ointment) Ointment, 0.005%, for treatment of plaque psoriasis in adults.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the enclosed labeling text. Accordingly, this supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, these submissions should be designated "FPL for approved supplement NDA 20-273/SE8-004." Approval of this submission by FDA is not required before the labeling is used.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, contact Kevin Darryl White, Project Manager, at (301) 827-2020.

Sincerely,

Jonathan K. Wilkin, M.D.
Director
Division of Dermatologic and Dental Drug Products
Office of Drug Evaluation V
Center for Drug Evaluation and Research

Enclosure